


# Publication writing and real world evidence

Annick Moon

# Publication mix



Based on 72 publications from 2004 to 2018

# Publication writing

- How does publication writing differ for interventional trials and observational studies?

# How to write a publication

1. Write the methods
2. Write the results
3. Write the introduction and the discussion

# Interventional trial: clinical study report



European Medicines Agency

July 1996  
CPMP/ICH/137/95

**ICH Topic E 3  
Structure and Content of Clinical Study Reports**

Step 5

**NOTE FOR GUIDANCE ON STRUCTURE AND CONTENT  
OF CLINICAL STUDY REPORTS  
(CPMP/ICH/137/95)**

TABLE OF CONTENTS	
INTRODUCTION TO THE GUIDELINE.....	6
STRUCTURE AND CONTENT OF CLINICAL STUDY REPORTS.....	8
1. TITLE PAGE.....	1
2. SYNOPSIS.....	8
3. TABLE OF CONTENTS FOR THE INDIVIDUAL CLINICAL STUDY REPORT.....	8
4. LIST OF ABBREVIATIONS AND DEFINITION OF TERMS.....	9
5. ETHICS.....	9
5.1 Independent Ethics Committee (IEC) or Institutional Review Board (IRB).....	9
5.2 Ethical Conduct of the Study.....	9
5.3 Patient Information and Consent.....	9
6. INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE.....	9
7. INTRODUCTION.....	10
8. STUDY OBJECTIVES.....	10
9. INVESTIGATIONAL PLAN.....	10
9.1 Overall Study Design and Plan-Description.....	10
9.2 Discussion of Study Design, including the Choice of Control Groups.....	11
9.3 Selection of Study Population.....	12
9.3.1 Inclusion criteria.....	12
9.3.2 Exclusion criteria.....	12
9.3.3 Removal of patients from therapy or assessment.....	12
9.4 Treatments.....	12
9.4.1 Treatments administered.....	12
9.4.2 Identity of investigational product(s).....	12
9.4.3 Method of assigning patients to treatment groups.....	13
9.4.4 Selection of doses in the study.....	13
9.4.5 Selection and timing of dose for each patient.....	13
9.4.6 Blinding.....	13
9.4.7 Prior and concomitant therapy.....	14
9.4.8 Treatment compliance.....	14
9.5 Efficacy and Safety Variables.....	14
9.5.1 Efficacy and safety measurements assessed and flow chart.....	14
9.5.2 Appropriateness of measurements.....	15
9.5.3 Primary efficacy variable(s).....	15
9.5.4 Drug concentration measurements.....	16
9.6 Data Quality Assurance.....	16
9.7 Statistical Methods Planned in the Protocol and Determination of Sample Size.....	16
9.7.1 Statistical and analytical plans.....	16

10.1 Disposition of Patients.....	17
10.2 Protocol Deviations.....	18
<b>11. EFFICACY EVALUATION.....</b>	<b>19</b>
11.1 Data Sets Analysed.....	19
11.2 Demographic and Other Baseline Characteristics.....	19
11.3 Measurements of Treatment Compliance.....	20
11.4 Efficacy Results and Tabulations of Individual Patient Data.....	20
11.4.1 Analysis of efficacy.....	20
11.4.2 Statistical/analytical issues.....	21
11.4.2.1 Adjustments for Covariates.....	21
11.4.2.2 Handling of Dropouts or Missing Data.....	22
11.4.2.3 Interim Analyses and Data Monitoring.....	22
11.4.2.4 Multicentre Studies.....	22
11.4.2.5 Multiple Comparisons/Multiplicity.....	23
11.4.2.6 Use of an "Efficacy Subset" of Patients.....	23
11.4.2.7 Active-Control Studies Intended to Show Equivalence.....	23
11.4.2.8 Examination of Subgroups.....	23
11.4.3 Tabulation of individual response data.....	23
11.4.4 Drug dose, drug concentration, and relationships to response.....	24
11.4.5 Drug-drug and drug-disease interactions.....	25
11.4.6 By-patient displays.....	25
11.4.7 Efficacy conclusions.....	25
<b>12. SAFETY EVALUATION.....</b>	<b>25</b>
12.1 Extent of Exposure.....	26
12.2 Adverse Events (AEs).....	26
12.2.1 Brief summary of adverse events.....	26
12.2.2 Display of adverse events.....	26
12.2.3 Analysis of adverse events.....	28
12.2.4 Listing of adverse events by patient.....	29
12.3 Deaths, Other Serious Adverse Events, and Other Significant Adverse Events.....	30
12.3.1 Listing of deaths, other serious adverse events, and other significant adverse events.....	30
12.3.1.1 Deaths.....	30
12.3.1.2 Other Serious Adverse Events.....	30
12.3.1.3 Other Significant Adverse Events.....	30
12.3.2 Narratives of deaths, other serious adverse events, and certain other significant adverse events.....	30
12.3.3 Analysis and discussion of deaths, other serious adverse events, and other significant adverse events.....	31
12.4 Clinical Laboratory Evaluation.....	31
12.4.1 Listing of individual laboratory measurements by patient (16.2.8) and each abnormal laboratory value (14.3.4).....	31

# CONSORT methods

Methods		
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio
	3b	Import changes to methods after trial commencement (such as eligibility criteria), with reasons
Participants	4a	Eligibility criteria for participants
	4b	Setting and locations where the data were collected
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed
	6b	Any changes to trial outcomes after the trial commenced, with reasons



5.3	Patient Information and Consent .....	9
<b>6.</b>	<b>INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE.....</b>	<b>9</b>
<b>7.</b>	<b>INTRODUCTION.....</b>	<b>10</b>
<b>8.</b>	<b>STUDY OBJECTIVES.....</b>	<b>10</b>
<b>9.</b>	<b>INVESTIGATIONAL PLAN.....</b>	<b>10</b>
9.1	Overall Study Design and Plan-Description.....	10
9.2	Discussion of Study Design, including the Choice of Control Groups .....	11
9.3	Selection of Study Population .....	12
9.3.1	Inclusion criteria.....	12
9.3.2	Exclusion criteria.....	12
9.3.3	Removal of patients from therapy or assessment .....	12
9.4	Treatments .....	12
9.4.1	Treatments administered .....	12
9.4.2	Identity of investigational product(s) .....	12
9.4.3	Method of assigning patients to treatment groups.....	13
9.4.4	Selection of doses in the study .....	13
9.4.5	Selection and timing of dose for each patient .....	13
9.4.6	Blinding .....	13
9.4.7	Prior and concomitant therapy.....	14
9.4.8	Treatment compliance .....	14
9.5	Efficacy and Safety Variables .....	14
9.5.1	Efficacy and safety measurements assessed and flow chart.....	14
9.5.2	Appropriateness of measurements.....	15
9.5.3	Primary efficacy variable(s) .....	15
9.5.4	Drug concentration measurements .....	16
9.6	Data Quality Assurance .....	16
9.7	Statistical Methods Planned in the Protocol and Determination of Sample Size .....	16
9.7.1	Statistical and analytical plans.....	16

Trial design

3a

3b

Participants

4a

4b

Interventions

5

Outcomes

6a

6b

## Methods

### Design and participants

This was a randomized, double-blind, placebo-controlled study of the efficacy of TIV in prevention of vaccine-matched, culture-confirmed influenza (VMCCI) conducted in the 2005-2006 and 2006-2007 influenza seasons in the US.

3a

The original primary outcome measure defined by the study protocol was the average vaccine efficacy over two consecutive seasons in the prevention of culture-confirmed influenza. In correspondence following the 2005-2006 season, the FDA Center for Biologics Evaluation and Research noted that the season was marked by a significant frequency of circulation of influenza virus strains that were antigenically-drifted from those in the vaccine, and required that the protocol be modified to assess the average efficacy against VMCCI across both seasons as the primary measure of vaccine efficacy.

3b

Male and female volunteers aged 18 to 49 years inclusive were eligible to participate if they were clinically healthy, understood the study procedures, had access to telephone contact throughout study, and provided informed written consent. In Season 1, eligible participants were enrolled at 37 centers, and in Season 2, eligible participants were enrolled at 44 centers.

4a

Exclusion criteria included: a significant acute or chronic, or medical or psychiatric illness requiring institution of new medical or surgical treatment, or a signifi-

4b



# CONSORT methods

Methods		
Randomisation Sequence generation	8a	Method used to generate the random allocation sequence
	8b	Type of randomisation; details of any restriction (such as blocking and block size)
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions
Blinding	11a 11b	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses

# Inferential analysis

- Determines if there is a relationship between an intervention and an outcome
- Determines the strength of the relationship

The analysis of the primary end point was done using the closed-test principle. As a first step, a 2-sided Cochran-Mantel-Haenszel test adjusted for the variable pooled center was used for the micafungin dose groups on a significance level of  $\alpha = 0.05$  to assess the difference between the dose groups. If the results allowed rejection of the null hypothesis of equality of the proportion  $p_x$  of patients with response (for  $H_0$ ,  $p_{50\text{mg}} = p_{100\text{mg}} = p_{150\text{mg}}$ ), then the groups were tested further with pairwise comparisons ( $p_{50\text{mg}} = p_{100\text{mg}}$ ,  $p_{50\text{mg}} = p_{150\text{mg}}$ ,  $p_{100\text{mg}} = p_{150\text{mg}}$ ), each at a significance level of  $\alpha = 0.05$ , using a 2-sided Cochran-Mantel-Haenszel test adjusted for the variable pooled center.

selected subset of participants (immunogenically sero-)

The primary efficacy analysis was based on the average efficacy over Seasons 1 and 2 and assessed the null hypothesis that the average efficacy in the actively immunized group was  $\leq 35\%$ , against the alternative hypothesis that average efficacy was  $>35\%$ . Average efficacy was defined as  $1 - v(R_1R_2) \times 100$  where  $R_1$  and  $R_2$  were the relative risks of a given disease endpoint in Seasons 1 and 2, respectively. A one-sided 97.5% CI was constructed for the average efficacy, and the TIV efficacy target was to be established if the lower bound of the CI was  $>35\%$ .

The secondary efficacy analysis was defined as the proportion of

# Descriptive analysis

- Describes the data: mean, median, standard deviation, confidence interval
  - Demographic data
  - Secondary outcomes
  - Safety data
- Occasionally primary outcome analysed descriptively

Solicited adverse events, unsolicited adverse events, and medically-attended adverse events were assessed in the reactogenicity and safety cohort. Serious adverse events and pIMDs were assessed in the total vaccinated cohort. We summarised reactogenicity and safety data with descriptive statistics and a two-sided 95% CI.

## **Analysis of Immunogenicity Endpoints**

HI responses were analyzed descriptively, and associated 95% confidence intervals (CIs) were calculated. GMTs of H5N1 antibodies were calculated using the mean log-transformed titer.

# Observational studies

Registry studies

National disease databases

Surveillance network studies

Medical records

Medical claims databases

Surveys

- Rare genetic disorders
- Surgery
- Transplantation
- Infectious disease

# Observational studies

- **Varied/new concepts**
- **Mass of information**


# Starting the publication

STROBE: Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objective	3	State specific objective, including any prespecified hypothesis



# Don't be a squid

Clear thoughts = clear writing



# Behind the ink

- Researchers/modellers/statisticians have written the methods/report/publication


They see

A clear description of the study using all  
the special scientific words

You see



# What was measured, how was it measured, and how was bias minimised?



**Publication**

1. Outcomes
2. Data sources
3. Statistics: confounders and adjusters

# How was bias minimised?

## STROBE: Methods

Variables	7	Clearly define all outcomes, exposures, predictors, <b>potential confounders, and effect modifiers</b> . Give diagnostic criteria if applicable
Data sources/measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any <b>efforts to address potential sources of bias</b>
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which grouping were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those <b>used to control for confounding</b> (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) Cohort study If applicable, explain how loss to follow-up was addressed Case-control study — if applicable, explain how matching of cases and controls was addressed Cross-sectional study – If applicable, describe analytical methods taking into account of sampling strategy (e) <b>Describe any sensitivity analyses</b>




# Research the statistical methods

- **Time series**
- **Immortal time bias**
- **Case-negative control**
- **Case-matched control**



# Publication development



# Writing the discussion

- **Interventional trial**
  - Presents the results in context of the literature
  - A paragraph on limitations describes the weaknesses of the study design
- **Observational trial**
  - Presents the results in context of potential confounders and how bias was addressed
  - Puts results in context of the literature

Thank you